Abstract
Aim:
To investigate the safety, tolerability and pharmacokinetics of intravenous hemoporfin, a novel photosensitive drug for the treatment of port-wine stain (PWS), in healthy Chinese volunteers following single-dose administration.
Methods:
Thirty-six healthy Chinese subjects were enrolled. The subjects were administered hemoporfin (2.5, 5, 7.5 or 10 mg/kg) via single-dose intravenous infusion. Pharmacokinetics of the drug were studied in the groups with doses of 2.5, 5 and 7.5 mg/kg, and tolerability was studied in all the 4 groups. Safety and tolerance were evaluated by monitoring adverse events and laboratory parameters, and pharmacokinetics were assessed by determining hemoporfin content with a validated high-performance liquid chromatography with fluorescence detection (HPLC/FLD) method.
Results:
Mild and transient adverse events occurred in the trial (n=10), but none were serious, and no subjects were withdrawn from the trial. The gastrointestinal tract adverse events, such as nausea, stomach upset, abdominal pain and vomiting, were observed in the groups with doses of 7.5 and 10 mg/kg. Increased alanine aminotransferase (ALT) concentration was found in 3 subjects, and increased alkaline phosphatase (ALP) concentration in one subject. The half-life of hemoporfin for doses of 2.5, 5, and 7.5 mg/kg was 1.26 h, 1.31 h, and 1.70 h, respectively. Cmax and AUC increased with dose for intravenous single-dose administration of hemoporfin in the 2.5, 5, and 7.5 mg/kg groups. Urinary excretion of hemoporfin within 12 h was less than 0.2%.
Conclusion:
Hemoporfin is safe and well-tolerated in healthy Chinese volunteers at a single intravenous dose of up to 10 mg/kg. It was rapidly cleared from the blood and had a short half-life, which insures a short light-avoidance period.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Jacobs AH, Walton RG . The incidence of birthmarks in the neonate. Pediatrics 1976; 58: 218–22.
Gu Y, Li J, Shan H, Wang K, Jiang Y, Zhang Y, et al. Clinical application of copper vapor laser in pdt for fifty cases of PWS. Chin J Laser Med Surg 1994; 3: 215–7.
Jasim ZF, Handley JM . Treatment of pulsed dye laser-resistant port wine stain birthmarks. J Am Acad Dermatol 2007; 57: 677–82.
Jiang L, Gu Y, Li X, Zhao X, Li J, Wang K, et al. Changes of skin perfusion after photodynamic therapy for port wine stain. Chin Med J (Engl) 1998; 111: 136–8.
Ouyang T, Cheng Y, Xing X . Clinical application of photodynamic therapy combined with non-coherent light (red light) for treatment of port-wine stains. Chin J Plast Surg Burn 1998; 14: 163–5.
Chen Y, Li H, Liu S . Treatment of nevas flammeus with copper vapor laser in photodynamic therapy. Acta Acad Med Hubei 1999; 20: 162–3.
Xu DY, Editor. Tumor photodynamic therapy. Beijing: Chinese Medical Science and Technology Press; 1996.
Qin ZP, Li KL, Ren L, Liu XJ . Photodynamic therapy of port wine stains-a report of 238 cases. Photodiagn Photodyn Ther 2007; 4: 53–9.
Song K, Kong B, Qu X, Li L, Yang Q . Phototoxicity of hemoporfin to ovarian cancer. Biochem Biophys Res Commun 2005; 337: 127–32.
Wei Y, Kong B, Song K, Qu X, Jin Q, Yang Q . Involvement of mitochondria-caspase pathway in hemoporfin-mediated cell death. Photochem Photobiol 2007; 83: 1319–24.
Liu F, Gu Y, Liu H, Fu Q, Zhu J, Pan Y, et al. An experimental study on the comparison of photodynamic effects of hematoporphyrin monomethyl ether and hematoporphyrin derivative. Chin J Laser Med Surg 2001; 10: 69–73.
Chen WH, Yu JX, Yao JZ, Shen WD, Liu JF, Xu DY . Pharmacokinetic studies hematoporphyrin monomethyl ether: a new promising drug for photodynamic therapy of tumors. Chin J Laser Med Surg 2000; 9: 105–8.
Du WM, Wang YM, Cheng NN . ADR confirmation and its research methods (2). Chin J Pharmacovigilance 2005; 2: 11–3.
Li P, Sun JG, Huang CR, Xu MJ, Li J, Lu H, et al. Determination of hematoporphyrin monomethyl ether in dogs plasma by HPLC using fluorescence detection. Chin J Laser Med Surg 2005; 14: 212–6.
Yu DK . The contribution of P-glycoprotein to pharmacokinetic drug-drug interactions. J Clin Pharmacol 1999; 39: 1203–11.
Schuetz EG, Furuya KN, Schuetz JD . Interindividual variation in expression of P-glycoprotein in normal human liver and secondary hepatic neoplasms. J Pharmacol Exp Ther 1995; 275: 1011–8.
Acknowledgements
We appreciate all the volunteers participating in this research. We are grateful to the nurses who participated in this study. We appreciate our colleagues X LIU and Q XIANG, who provided editorial assistance.
This study was sponsored by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co, Ltd. The work was funded by National Mega Project on Major Drug Development Research (2009ZX09401-001), key project of Science and Technology commission of Shanghai Municipality (064319003).
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Sun, Ph., Zhao, X., Zhou, Y. et al. Tolerance and pharmacokinetics of single-dose intravenous hemoporfin in healthy volunteers. Acta Pharmacol Sin 32, 1549–1554 (2011). https://doi.org/10.1038/aps.2011.132
Received:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/aps.2011.132
Keywords
This article is cited by
-
Hemoporfin-Mediated Photodynamic Therapy for Port-Wine Stains on Extremities
Dermatology and Therapy (2023)
-
Potential role of organic anion transporting polypeptide 1B1 (OATP1B1) in the selective hepatic uptake of hematoporphyrin monomethyl ether isomers
Acta Pharmacologica Sinica (2015)
